Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. METHODS: In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks. The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis after randomization. Secondary end points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of insulin. RESULTS: A significantly larger proportion of patients in the sotagliflozin group than in the placebo group achieved the primary end point (200 of 699 patients [28.6%] vs. 107 of 703 [15.2%], P<0.001). The least-squares mean change from baseline was significantly greater in the sotagliflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points), weight (-2.98 kg), systolic blood pressure (-3.5 mm Hg), and mean daily bolus dose of insulin (-2.8 units per day) (P≤0.002 for all comparisons). The rate of severe hypoglycemia was similar in the sotagliflozin group and the placebo group (3.0% [21 patients] and 2.4% [17], respectively). The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was significantly lower in the sotagliflozin group than in the placebo group. The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively). CONCLUSIONS: Among patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that received sotagliflozin than in the placebo group. However, the rate of diabetic ketoacidosis was higher in the sotagliflozin group. (Funded by Lexicon Pharmaceuticals; inTandem3 ClinicalTrials.gov number, NCT02531035 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Use of these processes may have contributed to the lower rates of ketoacidosis seen in some of the studies of these agents for adjunctive glycemic management in people with type 1 diabetes (314-316) compared with those that did not include preventative strategies (310,317).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [316]
In the citing paper
“Information on the safety and efficacy of combining MRAs with SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, ∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE participants were prescribed such a combination.153,718,719,721”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“FIDELIO-DKD and FIGARO-DKD excluded patients with a potassium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“The placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease) trials demonstrated for the non-steroidal MRA finerenone that these effects translate into reduced risk of kid”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationSGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Weissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050
Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., Lawrence, J. M., Liese, A. D., Liu, L. L., Mayer-Davis, E. J., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0669 · Cited by 484
8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Research works printed but not linked: 1
- Lyons SK, Diabetes Care
Cited by
Items 301–400 of 421
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.05.010 · Cited by 6
Fralick, M., & Kesselheim, A. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4994 · Cited by 2
“Based on the largest pre-approval trial for sotagliflozin, the rate of DKA was approximately 5 per 100 person-years.(9) Importantly, the clinical impact of DKA detected in clinical trials might be a substantial underestimate.”
BackgroundLi, Y., Li, H., Dong, L., Lin, D., Xu, L., Lou, P., Zang, D., Wang, K., & Ma, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923376 · Cited by 5
“According to the International Diabetes Federation (IDF), there are currently 29 million people worldwide who have T1DM (1).”
BackgroundMethodZhang, W., Yu, M., & Cheng, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1373314 · Cited by 4
Expanding Treatment Options for Improving Health Outcomes in Type 1 Diabetes
Garg, S. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.1807 · Cited by 4
Self-citationGarg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.2499 · Cited by 4
Self-citationEmpagliflozin as an adjunctive therapy for type 1 diabetes
MacIsaac, R. J., Lee, M. H., McAuley, S. A., Ward, G. M., & O'Neal, D. N. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.12.52 · Cited by 4
“They including the DEPICT (Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes) trials (19,21) and the inTandem-3 (A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) trial (…”
BackgroundWhich Patients with Heart Failure Benefit from an SGLT2 Inhibitor?
Benjamen, J., & Fralick, M. (2025) · NEJM Evidence · doi:10.1056/evidccon2400446 · Cited by 3
Aktürk, H. K., Karakus, K. E., Cengiz, D., Mason, E., Beck, E., Kaur, G., & Garg, S. K. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251398060 · Cited by 4
Self-citationWu, D., Wang, X., Liu, Q., & Luo, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16474 · Cited by 3
“16 20 The inclusion of injectable medications in these analyses complicates the accurate assessment of oral non-insulin antidiabetes drugs, as due to differences in administration routes, pharmacokinetics and patient adherence may confound efficacy comparisons.”
Ngan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112278 · Cited by 3
Kugathasan, L., Ragi, N., Debnath, S., Sridhar, V. S., Maity, S., Feng, T., Treviño, E., Perkins, B. A., Cherney, D. Z. I., & Sharma, K. (2025) · Physiological Reports · doi:10.14814/phy2.70465 · Cited by 3
Scavini, M., Bertuzzi, F., Girelli, A., Celleno, R., Molinari, C., Tripodi, F. P., Zanon, M. S., Bartolo, P. D., & Penna, G. L. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01386-7 · Cited by 3
A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes
Wentworth, J. M., Fourlanos, S., Colman, P. G., & Harrison, L. C. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100021 · Cited by 4
“Genital infection was not unexpected [9,10,12] and was mild to moderate in severity.”
BackgroundNovel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients
Naciu, A. M., & Pozzilli, P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1441288 · Cited by 3
“However, the rates of DKA and severe hypoglycemia among patients treated with sotagliflozin were higher, and this group of patients did not achieve the target HbA1c level compared to placebo [75].”
BackgroundSelf-citationNon-insulin therapies in addition to insulin in Type 1 DM treatment
Llano, A., & McKay, G. A. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa011 · Cited by 3
Konwar, M., Mamde, A., Patankar, P., Thatte, U. M., & Gogtay, N. (2021) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_78_21 · Cited by 3
Nakamura, Y., Horie, I., Yano, H., Nomoto, H., Fukui, T., Yuyama, Y., Kawamura, T., Ueda, M., Yamamoto, A., Hirota, Y., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061287 · Cited by 4
“Global clinical T1D trials have been conducted to examine additional indications for the use of SGLT2 inhibitors, including canagliflozin [5], dapagliflozin [6–8], empagliflozin [9], and sotagliflozin (a dual SGLT1/2 inhibitor) [10–12], for individuals with T1D.”
Kim, J., Wang, S., Marin, M., Sikirica, S., Anderson, M., & Shafrin, J. T. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.7.641 · Cited by 3
Naeem, M. H., Raza, M., Aziz, M. B., Ullah, N., Wahab, A., Khan, Z. A., & Farooq, H. (2025) · Cureus · doi:10.7759/cureus.90196 · Cited by 5
“Decision-making for insulin and oral agents should consider many individual patient factors such as disease severity, comorbidity, and patient preference [9].”
Wang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges
Hussain, M. S., Iyer, S., Liew, Y. J., Win, M. L., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7460084 · Cited by 2
Real-World Ketone Testing Patterns Among People Using FreeStyle Libre
Bergenstal, R. M., Virdi, N. S., Quadri, F., Curl, C. C., & Rahman, S. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261446059 · Cited by 2
Saha, S., Saha, S., & Gayen, M. (2023) · Journal of Diabetes and Metabolic Disorders · doi:10.1007/s40200-023-01192-7 · Cited by 2
“5, 5, and 10 mg) [49, 50, 55], ipragliflozin (50, 25, and 100 mg) [54, 58], and sotagliflozin (75, 200, and 400 mg) [16, 47, 48, 53, 57, 59].”
BackgroundUse of Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: The Promise and the Perils
Peter, P. R., & Inzucchi, S. E. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.022 · Cited by 3
Ngan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112284 · Cited by 2
European Association for the Study of Diabetes 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12617 · Cited by 2
den Mooter, L. V., Caerels, S., & Mathieu, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1450387 · Cited by 2
Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
Lingow, S. E., Burke, S. D., Brooks, A. D., & Rafferty, P. S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0058 · Cited by 2
“The inTandem 3 trial (12) evaluated the safety and efficacy of sotagliflozin, an SLGT1 and SLGT2 inhibitor, in 1,402 patients with type 1 diabetes over 24 weeks.”
BackgroundMethodMorkos, M., Nensey, N. K., & Bindal, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02017 · Cited by 2
Patoulias, D., & Keryttopoulos, P. (2018) · Gastroenterology Review · doi:10.5114/pg.2018.78291 · Cited by 2
“, despite the substantial differences in the number of involved patients and the short-term evaluation of the efficacy of sotagliflozin [6, 7].”
BackgroundAn Approach to Diabetic Ketoacidosis in an Emergency Setting
Pitocco, D., Leo, M. A. S. D., Tartaglione, L., Rizzo, E. G., Caputo, S., Rizzi, A., & Pontecorvi, A. (2020) · Reviews on Recent Clinical Trials · doi:10.2174/1574887115666200709172402 · Cited by 3
Dhatariya, K. (2022) · doi:10.1093/med/9780198870197.003.0265 · Cited by 1
Fisher, M., Llano, A., & McKay, G. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch5 · Cited by 1
Deniz, M. S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006990 · Cited by 1
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Petersen, M. C., Jones, K. E., Markov, A. M., Salam, M., Krutilova, P., McKee, A. M., Bohnert, K. L., Adamson, S. E., & McGill, J. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16324 · Cited by 1
“– 13,17, 19, 26 The magnitude of the pro-ketotic effect of SGLT2 inhibitors in T1D is of clinical interest.”
Shafrin, J. T., Wang, S., Kim, J., & Sikirica, S. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.4.386 · Cited by 1
Pathak, A., HARDIN, M. B., Girard, M., Davies, M. J., & Horton, W. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70266 · Cited by 1
Self-citationRole of Continuous Dual Glucose–Ketone Monitoring in Diabetes Care
Garg, S. K., & Parkin, C. G. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251369529 · Cited by 2
Self-citationOktavian, P., Salma, Z. N., Harjono, S., Kunigara, M. P., Iskak, Rahayu, D., Heru, R. A. S., Mudjanarko, S. W., Amin, I. M., & Wungu, C. D. K. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.016 · Cited by 1
Omrani, M. A., Baskaran, B. S., Sadeghi, H., Ahmadi, F., Eddin, L. E., Jafari, A., & Muanda, F. T. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2641874 · Cited by 2
Pandey, A., REPETTO, E., Perkins, C., Rossing, P. R., & Caramori, M. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70597 · Cited by 3
“The cardio-vascular outcomes findings support the need for large clinical trials on GLP-1RA and SGLT2i in T1D, which have often been limited by short follow-up and a focus on glycaemic control [5, 6, 8].”
Diabetes mellitus Typ 1 bei Kindern und Jugendlichen: Ernährung und Medikamente
Danne, T., & Biester, T. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-57309-9_46 · Cited by 1
Self-citationPerspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années
Scheen, A. J. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30043-9 · Cited by 2
“Des premiers résultats très prometteurs ont été rapportés récemment dans cette population [52].”
BackgroundSodium-Glucose Transporter Inhibitors and Diabetic Nephropathy in Humans and Animal Model
Nakhoul, R., Elias, K., Nakhoul, F. M., Dahan, I., Farber, E., Anam, H., & Nakhoul, N. (2018) · Journal of Clinical & Experimental Nephrology · doi:10.21767/2472-5056.100061 · Cited by 4
“Dapagliflozin, a potent and selective SGLT2-I, has been shown to have synergistic glycemic control in patients with type 2 diabetes when used in combination with metformin, or insulin [31-33].”
BackgroundDevelopments in the Management of Type 1 and Type 2 Diabetes
Mathieu, C. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.13 · Cited by 2
“CGM studies have also shown a more stable glucose profile.(7) There is no increase in severe hypoglycaemia but some increased risk of DKA has been seen depending on the study.”
BackgroundJiménez-Montero, J. G., Mora-Aguilar, C. J., & Chen-Ku, C. H. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0113 · Cited by 2
Novel Antidiabetic Therapies and Cardiovascular Risk Reduction
Thompson, J., Schacht, S., & Rothenberg, F. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.007 · Cited by 1
Tan, K. C. B., Chow, W., Leung, J. Y., Ho, A. Y. Y., Ozaki, R., Kam, G. Y. W., Li, J., Choi, C. C., Tsang, M., Chan, N. N., et al. (2019) · Hong Kong Medical Journal · doi:10.12809/hkmj197802 · Cited by 2
Gamad, N., Shafiq, N., & Malhotra, S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136569 · Cited by 1
Shen, X., & Shen, X. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14005 · Cited by 2
“insulin-independent reduction effect on blood glucose concentration.(29) All SGLT2is have a dual-receptor binding affinity for primarily renal-expressed SGLT1 and primarily intes-”
BackgroundMadhu, S., & Raizada, N. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.379597 · Cited by 1
Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
Yadegarfar, G., Livingston, M. A., Cortés, G., Alshames, R., Leivesley, K., Metters, A., Horne, L., Steele, T., & Heald, A. H. (2021) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000248 · Cited by 1
New Medications for the Treatment of Diabetes
Garg, S. K., & GIORDANO, D. A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2513 · Cited by 1
Self-citationAbbara, A., Clarke, S. A., Islam, R., Prague, J., Comninos, A. N., Narayanaswamy, S., Papadopoulou, D., Roberts, R. E., Izzi‐Engbeaya, C. N., Ratnasabapathy, R., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dex360 · Cited by 1
Zhou, X., Zhou, Y., Li, X., & Xiao, X. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14138 · Cited by 1
“An increased risk of limb amputation was reported in several observational studies compared with other treatments for type 2 diabetes.(6,12-15) The FDA issued a black box warning about amputations for patients using canagliflozin.”
ResultYesilyurt, Z. E., Karaömerlioğlu, İ., Erdoğan, B. R., Ozturk, G., Michel, M. C., & Arioglu‐Inan, E. (2021) · Research Square · doi:10.21203/rs.3.rs-526255/v1 · Cited by 1
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · doi:10.2337/figshare.29575130 · Cited by 3
SGLT-Hemmung bei Typ-1-Diabetes quo vadis?
Pampel, S. L. (2017) · Info Diabetologie · doi:10.1007/s15034-017-1173-4
11th Annual Symposium on Self-Monitoring of Blood Glucose: April 12–14, 2018, Oslo, Norway
Parkin, C. G., Homberg, A., & Hinzmann, R. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0284
SGLT-Hemmer als therapeutische Option bei Patienten mit Typ 1 Diabetes mellitus
Sourij, C., Obermayer, A. M., & Sourij, H. (2018) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0050-7
Il trattamento del diabete di tipo 1: dalle nuove insuline ai farmaci orali
Maurizi, A. R., Pieralice, S., & Pozzilli, P. (2019) · L Endocrinologo · doi:10.1007/s40619-019-00514-3
Self-citationDay, C. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.154
New Medications on the Horizon for Diabetes
Isaacs, D. M., & Bzowyckyj, A. S. (2019) · AADE in Practice · doi:10.1177/2325160319832061
Sodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes
Kim, C. H., & Moon, J. S. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.2.92
The future is now: SGLT2 inhibitors and type 1 diabetes – What about exercise?
Eckstein, M. L., Freitag, N., Schumann, M., Tripolt, N. J., Hofmann, P., Moser, O., & Sourij, H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107806 · Cited by 1
“[7] Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al.”
BackgroundGreenberg, C. A. (2018) · YorkSpace (York University)
Genetic Insights into Latent Autoimmune Diabetes in Adults
Mishra, R. (2019) · ScholarlyCommons (University of Pennsylvania)
12th Roche Diabetes Care Network Meeting: April 11–13, 2019, Copenhagen, Denmark
Parkin, C. G., Zepezauer, C., & Hinzmann, R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0392
Latres, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00036-1
Jermendy, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.9
Danjuma, M. I.-M., Al-Shokri, S. D., Saud, A. I. Y. A., Elshafei, M. N., Fatima, H., Doi, S. A. R., & Bidmos, M. A. (2019) · Medicine · doi:10.1097/md.0000000000018198
“Furthermore, newer agents within the SGLT2 inhibitor family such as Ertugliflozin,[8] Tofogliflozin,[9] Luseogliflozin,[10] Ipragliflozin,[11] and Sotagliflozin[12] amongst others have obtained the requisite market authorization and entered the therapeutic scene lately.”
Krempf, M. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30962-0 · Cited by 1
Atypische diabetische Ketoazidose bei Patienten mit Typ-2-Diabetes unter SGLT-2-Therapie
Kopf, S. (2020) · Diabetes aktuell · doi:10.1055/a-1095-4394
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
Morris, D. (2020) · Independent Nurse · doi:10.12968/indn.2020.4.14 · Cited by 1
SGLT inhibitors for type 1 diabetes
Das, G. C. (2020) · Practical Diabetes · doi:10.1002/pdi.2273
Toyoshima, J., Saitō, M., Kaibara, A., Isaka, H., & Sakatani, T. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.009
Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes
Jesus, A. R., Harrison, B. A., & Dore, T. M. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc277
Tackling hypoglycemia in children: teams, targets and technology
Danne, T. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.1
“Currently SGLT inhibitors represent the most effective compound of the possible class of adjunct agents.(57) The insulinindependent mechanism of action leading to more time in range and less glycemic variability(42) with the option of improving HbA1c with no increase or even a decrease in the rate of hypoglycemia.”
BackgroundSelf-citationKombinationstherapien mit Insulin bei Typ-1-Diabetes
Gallwitz, B. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00795-z
Veneti, S., & Τζιόμαλος, Κ. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967931
“55 mg/dl) was lower in the former [20].”
BackgroundChristidi, E. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0402336
Tratamento da hiperglicemia em pacientes com DM2 e insuficiência cardíaca
Saraiva, J. F. K., & Bertoluci, M. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-15
Diabetes mellitus Typ 1 bei Kindern und Jugendlichen: Ernährung und Medikamente
Danne, T., & Biester, T. (2018) · Springer Reference Medizin · doi:10.1007/978-3-662-52794-8_46-1
Self-citationPeters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · doi:10.2337/figshare.12824342.v1
Self-citationJENDLE, J. H., Ampudia‐Blasco, F. J., Füchtenbusch, M., & Pozzilli, P. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.1.1.12 · Cited by 2
Self-citationRenoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease
Yan, H., Wen, Y., & Liu, B. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2022-0009
Yeşilyurt, Z. E., Karaömerlioğlu, İ., Erdoğan, B. R., Ozturk, G., Michel, M. C., & Arioglu‐Inan, E. (2022) · Preprints.org · doi:10.20944/preprints202205.0346.v1
Adult-onset autoimmune diabetes
(2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00397-z
Strubbe, M., Caerels, S., David, K., Naesens, M., Vanassche, T., Mertens, A. C., & Mathieu, C. (2023) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.015
Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research
夏, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142429
Type 1 Diabetes - Causes, Treatments and Management
Zhao, R. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1003468
Cheng, Y., Li, H., Liu, X., Jin, X., Han, J., Du, J., & Xu, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1381248
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_3
Treatment of Obesity in Individuals with Type 1 Diabetes
Almehthel, M. S., & Alshehri, A. (2024) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2024.2332
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Cui, Y., Liu, H., & Dong, R. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04626-x
“Dipeptidyl peptidase 4 inhibitors [7, 9, 10], sodium-glucose cotransporter 2 inhibitors [7, 11, 12], and glucagon-like peptide 1 receptor agonists [7, 9, 13] can be taken into consideration, but more studies with larger cohort are required to further confirm that these therapies are capable of…”
Sun, Y., Zhang, Y., Zhang, J., Chen, Y. E., Jin, J.-P., Zhang, K., Mou, H., Liang, X., & Xu, J. (2024) · Figshare · doi:10.6084/m9.figshare.25271859
Metadata
- Authors
- Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., Danne, T., McGuire, D. K., Kushner, J. A., Peters, A., & Strumph, P.
- Affiliations
- University of Southern California (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-14
- Volume
- 377
- Issue
- 24
- Pages
- 2337-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2755899227
- Cited by
- 417
- References
- 34
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 38 · 2023: 36 · 2022: 32 · 2021: 41 · 2020: 57 · 2019: 72 · 2018: 64 · 2017: 10
- FWCI
- 43.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Wayne State University
- Alere
- University of Dundee
- Massachusetts Medical Society
- Intarcia Therapeutics
- Bigfoot Biomedical
- MannKind Corporation
- Dexcom
- AstraZeneca HealthCare Foundation
- University of Leicester
- Eisai
- Novo Nordisk
- Servier
- Mitsubishi Tanabe Pharma Corporation
- Esperion Therapeutics
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, SGLT2 inhibitors, insulin therapy, glycemic control, HbA1c, hypoglycemia, diabetic ketoacidosis, weight loss, systolic blood pressure, insulin dose reduction, combination therapy, drug safety and efficacy, insulin pump, insulin injection
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Least-Squares Analysis, Diabetic Ketoacidosis, Sodium-Glucose Transport Proteins, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.